17 results about "Olanzapine" patented technology

The invention relates to the technical field of drug detection, in particular to a molecularly imprinted sensor for quantitatively detecting olanzapine in human blood as well as a preparation method and application of the molecularly imprinted sensor. Au-Pt NSF is deposited on the surface of a substrate electrode through an HBDT method, then a molecularly imprinted polyaniline layer is prepared through electro-polymerization, and the molecularly imprinted sensor is formed. A classical redox probe potassium hexacyanoferrate is used as a tool, and DPV is used for monitoring current change (delta I) caused by olanzapine addition, so that sensitive quantitative detection of olanzapine is realized. The sensor prepared by the invention shows a good linear relationship to olanzapine in the concentration ranges of 0.005-0.4 mu M and 0.4-10 mu M, the detection limit is 0.94 nM, and the sensor has high reproducibility and stability (relative standard deviation RSDlt;

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar I disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

The invention discloses a composition, a method and a system for predicting the applicability of antipsychotic drugs. The invention develops a composition, a detection kit, a model construction method and a system for predicting the applicability of antipsychotic drugs on the basis of selected SNP site information. Particularly, a gene marker combination related to the curative effects of the antipsychotic drugs olanzapine, risperidone, aripiprazole and quetiapine is found by adopting a large-sample high-throughput whole-genome association analysis technology, and a corresponding mathematical model for predicting the curative effects is constructed; the model can be used for predicting the PANSS subtraction rate after the schizophrenia is treated by medication based on DNA polymorphic sites and clinical basic information of a medication user in a high, medium and low classification manner, and assists in guiding the selection of the types of the medication, so that personalized treatment of the schizophrenia patient is realized.

Kits and methods may be for treatments with olanzapine or a pharmaceutically acceptable salt thereof. The kit may include a container; at least one tray disposed in the container; a pre-filled syringe containing a diluent comprising a biodegradable polymer excipient, the pre-filled syringe being disposed in a first compartment of the tray; a vial containing a medicament comprising olanzapine, the vial being disposed in a second compartment of the tray; a dosing syringe configured to administer the medicament, the dosing syringe being disposed in a third compartment of the tray; a dosing needle configured to be attached to the dosing syringe, the dosing needle being disposed in a fourth compartment of the tray; a first indicia on the tray corresponding to the first compartment; and a second indicia on the tray corresponding to the second compartment, wherein the second indicia is different than the first indicia. The kit may include a warming pack, and methods of use may include warming the diluent from a substantially solid state using the warming pack. The diluent may further comprise an organic solvent such as dimethyl sulfoxide. The diluent may be transferred to the vial to reconstitute the medicament, and the reconstituted medicament may be stored for up to 24 hours before use.

This invention discloses the application of catalpol in the preparation of drugs for the prevention and treatment of schizophrenia and the alleviation of the glucose and lipid metabolism side effects of olanzapine. Using a schizophrenia model mouse model induced by the commonly used MK801, the therapeutic effect of catalpol on schizophrenia was investigated, and the therapeutic effect of catalpol on the glucose and lipid metabolism side effects of the commonly used drug olanzapine was investigated through long-term gavage administration. A systematic study of catalpol was conducted from pharmacodynamic, behavioral, and morphological perspectives. The results showed that catalpol effectively improved the behavioral characteristics of the schizophrenia model mice, alleviated negative symptoms and cognitive impairment; catalpol effectively improved olanzapine-induced obesity and lipid metabolism disorders. This provides a theoretical research basis for the development of catalpol into a drug for the treatment of schizophrenia.

The application discloses a kind of HPLC-MSMS method for simultaneously determining valproic acid, olanzapine and its metabolites in plasma, which comprises the following steps: S1. pretreatment of plasma samples with acetonitrile protein precipitation method;S2. HPLC-MSMS method is used to detect plasma samples, and qualitative and / or quantitative analysis of valproic acid, olanzapine and its metabolites in plasma is carried out simultaneously;Wherein, Agilent Poroshell 120EC-C18 column is selected as the chromatographic column;Electrospray ion source is used, and the mobile phase is A phase: formic acid water, B phase: acetonitrile;By optimizing the conditions of liquid phase and mass spectrometry, valproic acid, olanzapine and its metabolites are simultaneously determined by one method.The method has been applied to detect plasma samples of olanzapine and valproic acid combination, and olanzapine alone, and the measured results all meet the linear range.

The present disclosure provides pharmaceutical compositions for subcutaneous administration comprising olanzapine, an organic solvent, and a triblock copolymer and a diblock copolymer, and methods of treating psychiatric diseases and disorders using such compositions.

The invention relates to the technical field of depression resistance, in particular to a pharmaceutical composition and application thereof. According to the application disclosed by the invention, low-dose non-addictive dose nicotine is combined with an antipsychotic drug such as olanzapine to investigate the influence of the nicotine on the bipolar depression, so that the treatment effect on the bipolar depression can be synergistically improved, and the side effect caused by the antipsychotic drug is reduced.

Kits and methods may be for treatments with olanzapine or a pharmaceutically acceptable salt thereof. The kit may include a container; at least one tray disposed in the container; a pre-filled syringe containing a diluent comprising a biodegradable polymer excipient, the pre-filled syringe being disposed in a first compartment of the tray; a vial containing a medicament comprising olanzapine, the vial being disposed in a second compartment of the tray; a dosing syringe configured to administer the medicament, the dosing syringe being disposed in a third compartment of the tray; a dosing needle configured to be attached to the dosing syringe, the dosing needle being disposed in a fourth compartment of the tray; a first indicia on the tray corresponding to the first compartment; and a second indicia on the tray corresponding to the second compartment, wherein the second indicia is different than the first indicia. The kit may include a warming pack, and methods of use may include warming the diluent from a substantially solid state using the warming pack. The diluent may further comprise an organic solvent such as dimethyl sulfoxide. The diluent may be transferred to the vial to reconstitute the medicament, and the reconstituted medicament may be stored for up to 24 hours before use.

The invention relates to an olanzapine immunodetection reagent as well as a preparation method and a detection method thereof, in particular to an olanzapine chemiluminescence immunodetection reagent as well as a preparation method and a detection method thereof, and the olanzapine chemiluminescence immunodetection reagent comprises an anti-olanzapine specific antibody and an indicating reagent for detecting an anti-olanzapine specific antibody-olanzapine conjugate, the anti-olanzapine specific antibody is obtained by immunizing animals with olanzapine immunogen. The olanzapine immunogen has the beneficial effects that the olanzapine immunogen has strong specificity and high immunogenicity, and the prepared olanzapine specific antibody has strong specificity and high titer; a chemiluminescence immunoassay reagent containing the anti-olanzapine specific antibody can conveniently, quickly and accurately determine the olanzapine content in a sample, can simultaneously determine a plurality of samples on a full-automatic chemiluminescence immunoassay instrument, realizes high-flux quick determination of olanzapine, and is high in accuracy, strong in specificity and high in sensitivity. And the accuracy and the detection efficiency are greatly improved.

Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors in combination with a Compound of Formula VIII or a Compound of Formula IX, as described herein, or in combination with an antiemetic agent, such as an antipsychotic agent, e.g., olanzapine, for preventing or treating nausea and / or vomiting, e.g., CINV (chemotherapy-induced nausea and vomiting). In some embodiments, the Compound of Formula VIII or the Compound of Formula IX is used as mono-therapy (i.e., without a PDE1 inhibitor).

Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.

The invention relates to the field of medicine detection, in particular to an olanzapine blood concentration detection method. In the process of extracting olanzapine, a mode of firstly carrying out precipitation and then carrying out extraction is adopted, so that the recovery degree of olanzapine in blood can be improved, and the detection accuracy of olanzapine at a relatively low concentration is further improved.

The application relates to the field of drug detection, in particular to a method for detecting blood drug concentration of olanzapine. In the process of extracting olanzapine, the method adopts the mode of first precipitation and then extraction, which can improve the recovery degree of olanzapine in blood, and further improve the detection accuracy of olanzapine at a lower concentration.

Kits and methods may be for treatments with olanzapine or a pharmaceutically acceptable salt thereof. The kit may include a container; at least one tray disposed in the container; a pre-filled syringe containing a diluent comprising a biodegradable polymer excipient, the pre-filled syringe being disposed in a first compartment of the tray; a vial containing a medicament comprising olanzapine, the vial being disposed in a second compartment of the tray; a dosing syringe configured to administer the medicament, the dosing syringe being disposed in a third compartment of the tray; a dosing needle configured to be attached to the dosing syringe, the dosing needle being disposed in a fourth compartment of the tray; a first indicia on the tray corresponding to the first compartment; and a second indicia on the tray corresponding to the second compartment, wherein the second indicia is different than the first indicia. The kit may include a warming pack, and methods of use may include warming the diluent from a substantially solid state using the warming pack. The diluent may further comprise an organic solvent such as dimethyl sulfoxide. The diluent may be transferred to the vial to reconstitute the medicament, and the reconstituted medicament may be stored for up to 24 hours before use.

It relates to a novel method for personalizing a treatment for chemotherapy-induced nausea and vomiting (CINV) in a patient. SNP variations in genes HTR3A, HTR3B and TACR1 are utilized to predict the response to a particular anti-emetic regimen for a patient. Treatment regimens utilizing antagonists of 5-hydroxytryptamine type 3 (5-HT3R) receptor and neurokinin-1 (NK-1) receptor, with or without the addition of olanzapine are selected based on the patient genotype. In addition, a method has been generated to determine the genotypes of these genes and SNPs from VCF file output from high throughput sequencing.